Literature DB >> 23388726

3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses.

Jinzhi Tan1, Shyla George, Yuri Kusov, Markus Perbandt, Stefan Anemüller, Jeroen R Mesters, Helene Norder, Bruno Coutard, Céline Lacroix, Pieter Leyssen, Johan Neyts, Rolf Hilgenfeld.   

Abstract

We have determined the cleavage specificity and the crystal structure of the 3C protease of enterovirus 68 (EV68 3C(pro)). The protease exhibits a typical chymotrypsin fold with a Cys...His...Glu catalytic triad; its three-dimensional structure is closely related to that of the 3C(pro) of rhinovirus 2, as well as to that of poliovirus. The phylogenetic position of the EV68 3C(pro) between the corresponding enzymes of rhinoviruses on the one hand and classical enteroviruses on the other prompted us to use the crystal structure for the design of irreversible inhibitors, with the goal of discovering broad-spectrum antiviral compounds. We synthesized a series of peptidic α,β-unsaturated ethyl esters of increasing length and for each inhibitor candidate, we determined a crystal structure of its complex with the EV68 3C(pro), which served as the basis for the next design round. To exhibit inhibitory activity, compounds must span at least P3 to P1'; the most potent inhibitors comprise P4 to P1'. Inhibitory activities were found against the purified 3C protease of EV68, as well as with replicons for poliovirus and EV71 (50% effective concentration [EC(50)] = 0.5 μM for the best compound). Antiviral activities were determined using cell cultures infected with EV71, poliovirus, echovirus 11, and various rhinovirus serotypes. The most potent inhibitor, SG85, exhibited activity with EC(50)s of ≈180 nM against EV71 and ≈60 nM against human rhinovirus 14 in a live virus-cell-based assay. Even the shorter SG75, spanning only P3 to P1', displayed significant activity (EC(50) = 2 to 5 μM) against various rhinoviruses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23388726      PMCID: PMC3624371          DOI: 10.1128/JVI.01123-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model.

Authors:  A A Vaguine; J Richelle; S J Wodak
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-01-01

2.  Statistical estimations in enzyme kinetics.

Authors:  G N WILKINSON
Journal:  Biochem J       Date:  1961-08       Impact factor: 3.857

Review 3.  A case for developing antiviral drugs against polio.

Authors:  Marc S Collett; Johan Neyts; John F Modlin
Journal:  Antiviral Res       Date:  2008-05-13       Impact factor: 5.970

Review 4.  The molecular replacement method.

Authors:  M G Rossmann
Journal:  Acta Crystallogr A       Date:  1990-02-01       Impact factor: 2.290

5.  Development of potent inhibitors of the coxsackievirus 3C protease.

Authors:  Eui Seung Lee; Won Gil Lee; Soo-Hyeon Yun; Seong Hwan Rho; Isak Im; Sung Tae Yang; Saravanan Sellamuthu; Yong Jae Lee; Sun Jae Kwon; Ohkmae K Park; Eun-Seok Jeon; Woo Jin Park; Yong-Chul Kim
Journal:  Biochem Biophys Res Commun       Date:  2007-04-20       Impact factor: 3.575

6.  Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers.

Authors:  Frederick G Hayden; Ronald B Turner; Jack M Gwaltney; Kathy Chi-Burris; Merril Gersten; Poe Hsyu; Amy K Patick; George J Smith; Leora S Zalman
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

7.  Enterovirus 68 is associated with respiratory illness and shares biological features with both the enteroviruses and the rhinoviruses.

Authors:  M Steven Oberste; Kaija Maher; David Schnurr; Mary R Flemister; Judith C Lovchik; Heather Peters; Wendy Sessions; Carol Kirk; Nando Chatterjee; Susan Fuller; J Michael Hanauer; Mark A Pallansch
Journal:  J Gen Virol       Date:  2004-09       Impact factor: 3.891

Review 8.  Scaling and assessment of data quality.

Authors:  Philip Evans
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-12-14

9.  A versatile ligation-independent cloning method suitable for high-throughput expression screening applications.

Authors:  Nick S Berrow; David Alderton; Sarah Sainsbury; Joanne Nettleship; Rene Assenberg; Nahid Rahman; David I Stuart; Raymond J Owens
Journal:  Nucleic Acids Res       Date:  2007-02-22       Impact factor: 16.971

10.  Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents.

Authors:  Chih-Jung Kuo; Jiun-Jie Shie; Jim-Min Fang; Guei-Rung Yen; John T-A Hsu; Hun-Ge Liu; Sung-Nain Tseng; Shih-Cheng Chang; Ching-Yin Lee; Shin-Ru Shih; Po-Huang Liang
Journal:  Bioorg Med Chem       Date:  2008-06-13       Impact factor: 3.641

View more
  50 in total

1.  Enterovirus D68 Antivirals: Past, Present, and Future.

Authors:  Yanmei Hu; Rami Musharrafieh; Madeleine Zheng; Jun Wang
Journal:  ACS Infect Dis       Date:  2020-05-14       Impact factor: 5.084

2.  Phosphatidylinositol 4-kinase III beta is essential for replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo.

Authors:  Catherine Spickler; Julie Lippens; Marie-Kristine Laberge; Sophie Desmeules; Édith Bellavance; Michel Garneau; Tim Guo; Oliver Hucke; Pieter Leyssen; Johan Neyts; Fréderic H Vaillancourt; Anne Décor; Jeff O'Meara; Michael Franti; Annick Gauthier
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

3.  The enterovirus 3C protease inhibitor SG85 efficiently blocks rhinovirus replication and is not cross-resistant with rupintrivir.

Authors:  Céline Lacroix; Shyla George; Pieter Leyssen; Rolf Hilgenfeld; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

4.  Validating Enterovirus D68-2Apro as an Antiviral Drug Target and the Discovery of Telaprevir as a Potent D68-2Apro Inhibitor.

Authors:  Rami Musharrafieh; Chunlong Ma; Jiantao Zhang; Yanmei Hu; Jessica M Diesing; Michael T Marty; Jun Wang
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

Review 5.  Structural Biology of the Enterovirus Replication-Linked 5'-Cloverleaf RNA and Associated Virus Proteins.

Authors:  Steven M Pascal; Ravindranath Garimella; Meghan S Warden; Komala Ponniah
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-18       Impact factor: 11.056

6.  Enterovirus 68 3C protease cleaves TRIF to attenuate antiviral responses mediated by Toll-like receptor 3.

Authors:  Zichun Xiang; Linlin Li; Xiaobo Lei; Hongli Zhou; Zhuo Zhou; Bin He; Jianwei Wang
Journal:  J Virol       Date:  2014-03-26       Impact factor: 5.103

7.  Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68.

Authors:  Liang Sun; Adam Meijer; Mathy Froeyen; Linlin Zhang; Hendrik Jan Thibaut; Jim Baggen; Shyla George; John Vernachio; Frank J M van Kuppeveld; Pieter Leyssen; Rolf Hilgenfeld; Johan Neyts; Leen Delang
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

8.  The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon.

Authors:  J Rocha-Pereira; M S J Nascimento; Q Ma; R Hilgenfeld; J Neyts; D Jochmans
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

9.  3C Protease of Enterovirus D68 Inhibits Cellular Defense Mediated by Interferon Regulatory Factor 7.

Authors:  Zichun Xiang; Lulu Liu; Xiaobo Lei; Zhuo Zhou; Bin He; Jianwei Wang
Journal:  J Virol       Date:  2015-11-25       Impact factor: 5.103

10.  The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication.

Authors:  Aloys Tijsma; David Franco; Simon Tucker; Rolf Hilgenfeld; Mathy Froeyen; Pieter Leyssen; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.